Table 1.
Clinical features of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in Swiss Jackson Laboratory (SJL) mice upon treatment with carbon monoxide-releasing molecule (CORM)-A1, dexamethasone or vehicle.
| Experimental groups | Cumulative score 0–30 | Cumulative score 31–45 | Onset | Duration | Incidence % | Incidence after interr. (%) |
|---|---|---|---|---|---|---|
| CORM-A1 early prophylaxis (0–30) | 4·3 ± 7·3 | 2·8 ± 7·8 | 16·7 ± 1·5 | 2 ± 3·2 | 37·5 | 37·5 |
| CORM-A1 prophylaxis (0–16) | 15·3 ± 11·2 | 22·9 ± 4·6 | 10·9 ± 6·5 | 88·9 | ||
| CORM-A1 late prophylaxis (10–30) | 4·8 ± 9·4 | 20·7 ± 5·5 | 2·2 ± 4·2 | 30·0 | ||
| Dexamethasone | 6 ± 6·9 | 11·4 ± 11·6 | 18·4 ± 4·3 | 3·3 ± 3·2 | 62·5 | 75·0 |
| Vehicle | 19·6 ± 16 | 17·4 ± 14·1 | 17·5 ± 3·9 | 8·3 ± 6·0 | 85·7 | 85·7 |
| Mann–Whitney | ||||||
| CORM-A1 early prophylaxis (0–30) | 0·04 | 0·03 | 0·90 | 0·03 | ||
| CORM-A1 prophylaxis (0–16) | 0·94 | 0·71 | 0·31 | |||
| CORM-A1 late prophylaxis (10–30) | 0·05 | 0·36 | 0·05 | |||
| Dexamethasone | 0·07 | 0·34 | 0·65 | 0·06 |